https://en.bioecon.ru/capabilities/genome-eng/Recent content in Genome-Eng on BioeconHugoen-USTue, 18 Aug 2026 22:19:08 +0700https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Engineered oligonucleotides that recruit the cell’s endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, titratable alternative to DNA editing now in clinical validation, with Wave’s WVE-006 (AATD, RestorAATion-2) the lead asset and ProQR’s Axiomer platform delivering the first clinical proof of mechanism.https://en.bioecon.ru/technology/epigenome-editing/Fri, 03 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/epigenome-editing/Turning genes on or off by rewriting DNA methylation and histone marks with dCas9 fusion proteins or zinc fingers — no DNA sequence change, but an effect that can be inherited across cell divisions.https://en.bioecon.ru/technology/prime-editing/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/prime-editing/Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small indels without a double-strand break.https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.https://en.bioecon.ru/technology/base-editing/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/base-editing/Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.